Urgent.News

What's breaking now, across thousands of outlets.

Culture

Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint

(MedPage Today) -- Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD...

Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Culture

More from Wednesday 11 November →